Pharmacogenetics in the management of coumarin anticoagulant therapy: The way forward or an expensive diversion?

PLoS Medicine

Volumn 2, Issue 10, 2005, Pages 0944-0945

  Greaves, Mike ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; COUMARIN; PHENPROCOUMON; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); THROMBIN INHIBITOR; VITAMIN K GROUP; COUMARIN DERIVATIVE; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

ANTICOAGULANT THERAPY; BLEEDING; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SENSITIVITY; ETHNIC DIFFERENCE; ETHNIC GROUP; FOOD DRUG INTERACTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENETICS; RISK ASSESSMENT; SHORT SURVEY; THROMBOEMBOLISM; TRANSCRIPTION REGULATION; COST BENEFIT ANALYSIS; DRUG RESISTANCE; ECONOMICS; GENETICS; NOTE;

ANTICOAGULANTS; COST-BENEFIT ANALYSIS; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; HUMANS; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC; THROMBOEMBOLISM;

EID: 27644541797     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0020342     Document Type: Short Survey

References (11)

1. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, et al. (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427: 541-544.
2. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, et al. (1996) Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348: 423-428.
3. Panneerselvam S, Baglin C, Lefort W, Baglin T (1998) Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Brit J Haematol 103: 422-424.
4. Lubetsky A, Dekel-Stem E, Chetrit A, Lubin F, Halkin H (1999) Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thrombos Haemostas 81: 396-399.
5. Yu HC, Chan TY, Critchley JA, Woo KS (1996) Factors determining the maintenance dose of warfarin in Chinese patients. QJM 89: 127-135.
6. Dang MT, Hambleton J, Kayser SR (2005) The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother 39: 1008-1012.
7. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl J Med 352: 2285-2293.
8. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of overanticoagulation in patients on long-term treatment. Blood 96: 1816-1819.
9. D'Ambrosio RL, D'Andrea G, Cappucci F, Chetta M, Di Perna P, et al. (2004) Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica 89: 1510-1516.
10. Higashi MK, Veenstra DL, Kondo LM, Wittkowski AK, Srinouanprachanh SL, et al. (2002) Association between CYP2C9 genetic variants and anticoagulant- related outcomes during warfarin therapy. JAMA 287: 1690-1698.
11. Reitsma P, Van der Heijden J, Groot A, Rosendaal F, Büller H (2005) A C1173T dimorphism in the VRKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2: e312. DOI: 10.1371/journal.pmed.0020312